A novel antibody-like TCRγδ-Ig fusion protein exhibits antitumor activity against human ovarian carcinoma

Cancer Letters

Volumn 341, Issue 2, 2013, Pages 150-158

  Zheng, Jing ^a   Guo, Yang ^a   Ji, Xu ^a   Cui, Lianxian ^a   He, Wei ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

ADCC; TCR ; Tumor targeted immunotherapy; Xenograft model

Indexed keywords

ANTINEOPLASTIC AGENT; TCR GAMMA DELTA IG FUSION PROTEIN; UNCLASSIFIED DRUG; ANTIBODY; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CONFOCAL MICROSCOPY; DRUG EFFECTS; DRUG SCREENING; FLOW CYTOMETRY; GENETICS; HELA CELL LINE; IMMUNOLOGY; K562 CELL LINE; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; PROTEIN ENGINEERING; SURVIVAL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HELA CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; K562 CELLS; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; OVARIAN NEOPLASMS; PROTEIN ENGINEERING; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887206733     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.07.036     Document Type: Article

References (47)

1. Rapoport A.P., Stadtmauer E.A., Aqui N., Badros A., Cotte J., Chrisley L., Veloso E., Zheng Z., Westphal S., Mair R., Chi N., Ratterree B., Pochran M.F., Natt S., Hinkle J., Sickles C., Sohal A., Ruehle K., Lynch C., Zhang L., Porter D.L., Luger S., Guo C., Fang H.B., Blackwelder W., Hankey K., Mann D., Edelman R., Frasch C., Levine B.L., Cross A., June C.H. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 2005, 11:1230-1237.
2. Ochi T., Fujiwara H., Yasukawa M. Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia. J. Biomed. Biotechnol. 2010, 2010:521248. 10.1155/2010/521248.
3. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., Provost N., Frohlich M.W. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
4. Besser M.J., Shapira-Frommer R., Treves A.J., Zippel D., Itzhaki O., Hershkovitz L., Levy D., Kubi A., Hovav E., Chermoshniuk N., Shalmon B., Hardan I., Catane R., Markel G., Apter S., Ben-Nun A., Kuchuk I., Shimoni A., Nagler A., Schachter J. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 2010, 16:2646-2655.
5. Peng L., Kjaergaard J., Plautz G.E., Awad M., Drazba J.A., Shu S., Cohen P.A. Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J. Immunol. 2002, 169:4811-4821.
6. McKee M.D., Fichera A., Nishimura M.I. T cell immunotherapy. Front Biosci. 2007, 12:919-932.
7. Dudley M.E., Wunderlich J.R., Shelton T.E., Even J., Rosenberg S.A. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J. Immunother. 2003, 26:332-342.
8. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Slamon D.J., Murphy M., Novotny W.F., Burchmore M., Shak S., Stewart S.J. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001, 61(Suppl 2):37-42.
9. Hainsworth J.D., Litchy S., Burris H.A., Scullin D.C., Corso S.W., Yardley D.A., Morrissey L., Greco F.A. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J. Clin. Oncol. 2002, 20:4261-4267.
10. Molloy P.E., Sewell A.K., Jakobsen B.K. Soluble T cell receptors: novel immunotherapies. Curr. Opin. Pharmacol. 2005, 5:438-443.
11. Boulter J.M., Jakobsen B.K. Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens. Clin. Exp. Immunol. 2005, 142:454-460.
12. Epel M., Ellenhorn J.D., Diamond D.J., Reiter Y. A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells. Cancer Immunol. Immunother. 2002, 51:565-573.
13. Card K.F., Price-Schiavi S.A., Liu B., Thomson E., Nieves E., Belmont H., Builes J., Jiao J.A., Hernandez J., Weidanz J., Sherman L., Francis J.L., Amirkhosravi A., Wong H.C. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunol. Immunother. 2004, 53:345-357.
14. Belmont H.J., Price-Schiavi S., Liu B., Card K.F., Lee H.I., Han K.P., Wen J., Tang S., Zhu X., Merrill J., Chavillaz P.A., Wong J.L., Rhode P.R., Wong H.C. Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion protein. Clin. Immunol. 2006, 121:29-39.
15. Wen J., Zhu X., Liu B., You L., Kong L., Lee H.I., Han K.P., Wong J.L., Rhode P.R., Wong H.C. Targeting activity of a TCR/IL-2 fusion protein against established tumors. Cancer Immunol. Immunother. 2008, 57:1781-1794.
16. Mosquera L.A., Card K.F., Price-Schiavi S.A., Belmont H.J., Liu B., Builes J., Zhu X., Chavaillaz P.A., Lee H.I., Jiao J.A., Francis J.L., Amirkhosravi A., Wong R.L., Wong H.C. In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein. J. Immunol. 2005, 174:4381-4388.
17. Morita C.T., Beckman E.M., Bukowski J.F., Tanaka Y., Band H., Bloom B.R., Golan D.E., Brenner M.B. Direct presentation of nonpeptide prenyl pyrophosphate antigens to human gamma delta T cells. Immunity 1995, 3:495-507.
18. Kreslavsky T., von Boehmer H. GammadeltaTCR ligands and lineage commitment. Semin. Immunol. 2010, 22:214-221.
19. Wrobel P., Shojaei H., Schittek B., Gieseler F., Wollenberg B., Kalthoff H., Kabelitz D., Wesch D. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand. J. Immunol. 2007, 66:320-328.
20. Nedellec S., Bonneville M., Scotet E. Human Vgamma9Vdelta2 T cells: from signals to functions. Semin. Immunol. 2010, 22:199-206.
21. Xu C., Zhang H., Hu H., He H., Wang Z., Xu Y., Chen H., Cao W., Zhang S., Cui L., Ba D., He W. Gammadelta T cells recognize tumor cells via CDR3delta region. Mol. Immunol. 2007, 44:302-310.
22. Wang Z., Zhang T., Hu H., Zhang H., Yang Z., Cui L., He W. Targeting solid tumors via T cell receptor complementarity-determining region 3delta in an engineered antibody. Cancer Lett. 2008, 272:242-252.
23. Wang H., Fang Z., Morita C.T. Vgamma2Vdelta2 T Cell Receptor recognition of prenyl pyrophosphates is dependent on all CDRs. J. Immunol. 2010, 184:6209-6222.
24. Gomes A.Q., Correia D.V., Grosso A.R., Lanca T., Ferreira C., Lacerda J.F., Barata J.T., Silva M.G., Silva-Santos B. Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells. Haematologica 2010, 95:1397-1404.
25. Villamor N., Montserrat E., Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin. Oncol. 2003, 30:424-433.
26. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
27. Shin S., El-Diwany R., Schaffert S., Adams E.J., Garcia K.C., Pereira P., Chien Y.H. Antigen recognition determinants of gammadelta T cell receptors. Science 2005, 308:252-255.
28. Zhao H., Xi X., Cui L., He W. CDR3delta -grafted gamma9delta2T cells mediate effective antitumor reactivity. Cell Mol Immunol 2011, 9:147-154.
29. Xi X., Guo Y., Chen H., Xu C., Zhang H., Hu H., Cui L., Ba D., He W. Antigen specificity of gammadelta T cells depends primarily on the flanking sequences of CDR3delta. J. Biol. Chem. 2009, 284:27449-27455.
30. Bukowski J.F., Morita C.T., Tanaka Y., Bloom B.R., Brenner M.B., Band H. V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. J. Immunol. 1995, 154:998-1006.
31. Verma B., Neethling F.A., Caseltine S., Fabrizio G., Largo S., Duty J.A., Tabaczewski P., Weidanz J.A. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. J. Immunol. 2010, 184:2156-2165.
32. Reiman J.M., Kmieciak M., Manjili M.H., Knutson K.L. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin. Cancer Biol. 2007, 17:275-287.
33. Chien Y.H., Konigshofer Y. Antigen recognition by gammadelta T cells. Immunol. Rev. 2007, 215:46-58.
34. Kong Y., Cao W., Xi X., Ma C., Cui L., He W. The NKG2D ligand ULBP4 binds to TCRgamma9/delta2 and induces cytotoxicity to tumor cells through both TCRgammadelta and NKG2D. Blood 2009, 114:310-317.
35. Tanaka Y., Morita C.T., Tanaka Y., Nieves E., Brenner M.B., Bloom B.R. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 1995, 375:155-158.
36. Gober H.J., Kistowska M., Angman L., Jeno P., Mori L., De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 2003, 197:163-168.
37. Vantourout P., Mookerjee-Basu J., Rolland C., Pont F., Martin H., Davrinche C., Martinez L.O., Perret B., Collet X., Perigaud C., Peyrottes S., Champagne E. Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. J. Immunol. 2009, 183:3848-3857.
38. Scotet E., Martinez L.O., Grant E., Barbaras R., Jeno P., Guiraud M., Monsarrat B., Saulquin X., Maillet S., Esteve J.P., Lopez F., Perret B., Collet X., Bonneville M., Champagne E. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 2005, 22:71-80.
39. Mookerjee-Basu J., Vantourout P., Martinez L.O., Perret B., Collet X., Perigaud C., Peyrottes S., Champagne E. F1-adenosine triphosphatase displays properties characteristic of an antigen presentation molecule for Vgamma9Vdelta2 T cells. J. Immunol. 2010, 184:6920-6928.
40. Chen H., He X., Wang Z., Wu D., Zhang H., Xu C., He H., Cui L., Ba D., He W. Identification of human T cell receptor gammadelta-recognized epitopes/proteins via CDR3delta peptide-based immunobiochemical strategy. J. Biol. Chem. 2008, 283:12528-12537.
41. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
42. Graff C.P., Wittrup K.D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003, 63:1288-1296.
43. Starr T.K., Jameson S.C., Hogquist K.A. Positive and negative selection of T cells. Annu. Rev. Immunol. 2003, 21:139-176.
44. Holler P.D., Holman P.O., Shusta E.V., O'Herrin S., Wittrup K.D., Kranz D.M. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA 2000, 97:5387-5392.
45. Alli R., Zhang Z.M., Nguyen P., Zheng J.J., Geiger T.L. Rational design of T cell receptors with enhanced sensitivity for antigen. PLoS One 2011, 6:e18027.
46. Stavenhagen J.B., Gorlatov S., Tuaillon N., Rankin C.T., Li H., Burke S., Huang L., Vijh S., Johnson S., Bonvini E., Koenig S. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res. 2007, 67:8882-8890.
47. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., Hanai N., Shitara K. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 2003, 278:3466-3473.